Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MLNT

Melinta Therapeutics (MLNT)

Melinta Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MLNT
DateTimeSourceHeadlineSymbolCompany
04/16/20188:00AMGlobeNewswire Inc.Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings fr...NASDAQ:MLNTMelinta Therapeutics Inc
03/27/201812:42PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MLNTMelinta Therapeutics Inc
03/16/20188:19AMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:MLNTMelinta Therapeutics Inc
03/14/20188:00AMGlobeNewswire Inc.Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare ConferenceNASDAQ:MLNTMelinta Therapeutics Inc
03/14/20186:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MLNTMelinta Therapeutics Inc
03/13/20184:35PMGlobeNewswire Inc.Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement WeatherNASDAQ:MLNTMelinta Therapeutics Inc
03/13/20189:05AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MLNTMelinta Therapeutics Inc
03/13/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsNASDAQ:MLNTMelinta Therapeutics Inc
03/08/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in EuropeNASDAQ:MLNTMelinta Therapeutics Inc
03/02/20187:00AMGlobeNewswire Inc.Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care ConferenceNASDAQ:MLNTMelinta Therapeutics Inc
02/28/20187:00AMGlobeNewswire Inc.Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018NASDAQ:MLNTMelinta Therapeutics Inc
02/27/20184:05PMGlobeNewswire Inc.Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Pati...NASDAQ:MLNTMelinta Therapeutics Inc
02/20/20187:00AMGlobeNewswire Inc.Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxac...NASDAQ:MLNTMelinta Therapeutics Inc
01/29/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United StatesNASDAQ:MLNTMelinta Therapeutics Inc
01/18/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial VaginosisNASDAQ:MLNTMelinta Therapeutics Inc
01/08/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease PortfolioNASDAQ:MLNTMelinta Therapeutics Inc
01/08/20187:00AMBusiness WireThe Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta TherapeuticsNASDAQ:MLNTMelinta Therapeutics Inc
01/03/20187:00AMGlobeNewswire Inc.Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare ConferenceNASDAQ:MLNTMelinta Therapeutics Inc
01/02/20187:00AMGlobeNewswire Inc.Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor RelationsNASDAQ:MLNTMelinta Therapeutics Inc
11/29/20177:00AMGlobeNewswire Inc.Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines CompanyNASDAQ:MLNTMelinta Therapeutics Inc
11/13/20177:00AMGlobeNewswire Inc.Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of AcneNASDAQ:MLNTMelinta Therapeutics Inc
11/06/20178:00AMGlobeNewswire Inc.Melinta Therapeutics Announces Successful Completion of MergerNASDAQ:MLNTMelinta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MLNT

Your Recent History

Delayed Upgrade Clock